Lutikizumab

N/A

Report date: 2026/02/10 20:00:22

Base Information

Drug NameLutikizumab

Drug Alias NameABT-981

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin-1 alpha inhibitorsInterleukin-1 beta inhibitors

TargetsInterleukin-1 alphaInterleukin-1 beta

Therapy Area/IndicationsDermatitis, AtopicCrohn DiseaseColitis, Ulcerative +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[46]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc

Inactive CompaniesN/A

Active IndicationsDermatitis, AtopicCrohn DiseaseColitis, Ulcerative +[4]

Inactive IndicationsOsteoarthritis, KneeOsteoarthritis

Other Information

ATC CodeN/A